Affinage

NUAK1

NUAK family SNF1-like kinase 1 · UniProt O60285

Length
661 aa
Mass
74.3 kDa
Annotated
2026-04-29
93 papers in source corpus 37 papers cited in narrative 39 extracted findings

Mechanistic narrative

Synthesis pass · prose summary of the discoveries below

NUAK1 is an AMPK-related serine/threonine kinase that functions as a central signaling node integrating metabolic stress, cytoskeletal regulation, and gene expression control across diverse cellular contexts. Activated by LKB1 phosphorylation at Thr211 and cooperatively by Akt at Ser600 and NDR2 at the T-loop, NUAK1 phosphorylates the PP1β-MYPT1 phosphatase complex to regulate myosin phosphorylation, centrosome duplication, and NRF2 nuclear import via the GSK3β axis, and directly phosphorylates substrates including caspase-6 (Ser257), LATS1 (Ser464), p53, tau (Ser356), PNUTS, Akt (Ser473), NADK (Ser64), and hnRNP A1 (PMID:16488889, PMID:15273717, PMID:19927127, PMID:21317932, PMID:27720485, PMID:32006464, PMID:38135881, PMID:39159134, PMID:35963429). In neurons, the LKB1–NUAK1 pathway controls axon branching by immobilizing mitochondria at nascent presynaptic sites and by sustaining mitochondrial metabolic activity through the microprotein BRAWNIN; NUAK1 haploinsufficiency impairs cortical connectivity and causes behavioral deficits consistent with autism spectrum disorder (PMID:23791179, PMID:38514619, PMID:30327473). In the nucleus, NUAK1 phosphorylates PNUTS to locally inhibit PP1 and support spliceosome function and nascent RNA synthesis, while in fibroblasts it drives a positive-feedback loop with YAP/TAZ and TGF-β/SMAD signaling that promotes organ fibrosis (PMID:32006464, PMID:35320001, PMID:40310323).

Mechanistic history

Synthesis pass · year-by-year structured walk · 21 steps
  1. 2003 Medium

    NUAK1 was first linked to cell survival signaling when overexpression was shown to suppress nutrient-starvation- and death-receptor-induced apoptosis by inhibiting caspase-8 activation, establishing it as a pro-survival kinase.

    Evidence Overexpression in HepG2 cells with caspase-8, Bid, and FLIP readouts

    PMID:13679856

    Open questions at the time
    • Mechanism of caspase-8 inhibition not defined at the substrate level
    • Single cell line, no genetic loss-of-function
  2. 2004 High

    The first direct substrate of NUAK1 was identified—caspase-6 at Ser257—providing a molecular mechanism for its anti-apoptotic function and demonstrating it is a bona fide kinase with defined substrates.

    Evidence In vitro kinase assay with S257A mutagenesis abolishing protection from Fas-mediated death in colorectal cancer cells

    PMID:15273717

    Open questions at the time
    • Whether caspase-6 phosphorylation is relevant in non-cancer contexts
    • Structural basis of kinase-substrate recognition unknown
  3. 2006 High

    The activation mechanism of NUAK1 was elucidated: NDR2 phosphorylates Thr211 on the T-loop and Akt phosphorylates Ser600 in the regulatory domain, with both events required for full kinase activity, placing NUAK1 downstream of growth factor signaling.

    Evidence In vitro kinase assay with mutant constructs and co-IP upon IGF-1 stimulation in colorectal cancer cells

    PMID:16488889

    Open questions at the time
    • Whether LKB1 and NDR2 phosphorylate the same site independently or cooperatively
    • Context-dependence of NDR2 vs. LKB1 activation not resolved
  4. 2009 High

    NUAK1 was connected to cell cycle and ploidy control through its phosphorylation of LATS1 at Ser464, triggering LATS1 degradation and linking NUAK1 to Hippo pathway regulation and cellular senescence.

    Evidence Loss-of-function screen, in vitro kinase assay, and dominant-negative LATS1 phenocopy in human fibroblasts

    PMID:19927127

    Open questions at the time
    • Whether NUAK1-LATS1 interaction operates in Hippo-dependent tissue growth contexts
    • Ubiquitin ligase mediating LATS1 degradation downstream of Ser464 phosphorylation not identified
  5. 2011 High

    NUAK1 was shown to phosphorylate p53 in an LKB1-dependent manner and to occupy the p21 promoter with p53, establishing a tumor-suppressive LKB1/NUAK1/p53/p21 axis that induces G1/S arrest.

    Evidence Co-IP, in vitro kinase assay, ChIP at the p21 promoter, cell cycle analysis

    PMID:21317932

    Open questions at the time
    • Specific p53 phosphorylation site(s) not mapped
    • How this tumor-suppressive function is reconciled with NUAK1's pro-survival roles
  6. 2013 High

    NUAK1 was placed in a neurodevelopmental pathway: the LKB1–NUAK1 axis controls cortical axon branching by immobilizing mitochondria at nascent presynaptic sites via Syntaphilin, revealing a cell-biological function beyond cancer.

    Evidence Conditional LKB1 knockout, in utero NUAK1 knockdown/overexpression, Syntaphilin rescue in mouse cortical neurons

    PMID:23791179

    Open questions at the time
    • Whether NUAK1 directly phosphorylates Syntaphilin or acts indirectly
    • Mechanism linking mitochondrial immobilization to branch stabilization unknown
  7. 2014 High

    A cell-cycle-linked regulatory circuit was defined: CDK phosphorylation primes NUAK1 for PLK1-mediated phosphorylation and SCFβTrCP-dependent degradation, while NUAK1 reciprocally promotes PLK1 activation by inhibiting PP1β-MYPT1, establishing the MYPT1/PP1β complex as a central NUAK1 effector.

    Evidence Biochemical reconstitution of CDK→PLK1→βTrCP ubiquitylation cascade, site-directed mutagenesis, NUAK1 inhibitors WZ4003/HTH-01-015

    PMID:24785407

    Open questions at the time
    • Whether PP1β-MYPT1 inhibition by NUAK1 involves direct MYPT1 phosphorylation or an indirect mechanism
    • Functional consequence of NUAK1 degradation timing on mitotic fidelity
  8. 2016 High

    NUAK1 was identified as a kinase that phosphorylates tau at Ser356, stabilizing pathological tau; genetic reduction of NUAK1 suppressed neurodegeneration in both Drosophila and mouse tauopathy models, establishing NUAK1 as a therapeutic target for tauopathies.

    Evidence In vitro kinase assay, Drosophila genetic screen, NUAK1 haploinsufficiency rescue in P301S tau mouse model

    PMID:27720485

    Open questions at the time
    • Whether NUAK1 phosphorylates tau directly in neurons or through an intermediate
    • Therapeutic window of NUAK1 inhibition given its essential neurodevelopmental roles
  9. 2017 Medium

    An alternative, LKB1-independent activation mechanism was uncovered: in LKB1-null tumors, calcium/PKCα signaling maintains NUAK1 activity to engage the AMPK-TORC1 metabolic checkpoint, explaining how NUAK1 remains functional in LKB1-deficient cancers.

    Evidence PKCα knockdown/inhibition and calcium manipulation in LKB1-null cell models with TORC1 readouts

    PMID:29106388

    Open questions at the time
    • Whether PKCα directly phosphorylates NUAK1 and at which site
    • Generalizability beyond MYC-driven LKB1-null contexts
  10. 2018 High

    NUAK1 was connected to the antioxidant stress response: it facilitates NRF2 nuclear import by inhibiting PP1β, thereby activating AKT and suppressing GSK3β-dependent NRF2 phosphorylation; conditional NUAK1 deletion caused regression of established colorectal tumors, positioning NUAK1 as a druggable vulnerability in ROS-dependent cancers.

    Evidence Conditional KO in autochthonous colorectal tumor models with NRF2/PP1β/AKT/GSK3β pathway dissection

    PMID:29500295

    Open questions at the time
    • Whether NUAK1 directly phosphorylates PP1β or MYPT1 in this context
    • NRF2-independent mechanisms of tumor regression upon NUAK1 loss
  11. 2018 High

    NUAK1 haploinsufficiency in mice was shown to impair cortical axon branching and produce behavioral deficits including defective spatial memory, impaired social novelty, and abnormal sensorimotor gating, validating NUAK1 as a haploinsufficient autism spectrum disorder candidate gene.

    Evidence Heterozygous NUAK1 knockout mice with cortical connectivity analysis and behavioral test battery

    PMID:30327473

    Open questions at the time
    • No human family studies confirming NUAK1 haploinsufficiency as causative for ASD
    • Molecular mechanism linking reduced kinase dosage to circuit-level defects unclear
  12. 2020 High

    The nuclear function of NUAK1 was defined: it phosphorylates the PP1 regulatory subunit PNUTS to locally inhibit PP1, supporting spliceosome activity and nascent RNA synthesis; in MYC-overexpressing cells, NUAK1 inhibition causes global RNAPII pausing, revealing a transcription-coupled splicing role.

    Evidence Nuclear interactome by mass spectrometry, in vitro PNUTS phosphorylation, RNAPII ChIP, spliceosome and nascent RNA assays

    PMID:32006464

    Open questions at the time
    • Specific PNUTS phosphorylation sites not mapped
    • Whether NUAK1-PNUTS axis is MYC-selective or generalizable
  13. 2020 Medium

    Subcellular compartmentalization of NUAK1 was shown to differentially control metabolism: cytosolic NUAK1 enhances mitochondrial respiration and ATP production, whereas nuclear NUAK1 promotes glycolysis, establishing NUAK1 as a localization-dependent metabolic switch.

    Evidence Subcellular fractionation with mitochondrial respiration assays and ATP measurements in cancer cells

    PMID:32754444

    Open questions at the time
    • Cytoplasmic substrates mediating mitochondrial effects not identified
    • Single study; compartment-specific constructs not used
  14. 2022 High

    NUAK1 was shown to drive organ fibrosis through a TGF-β–YAP/TAZ positive feedback loop: TGF-β induces NUAK1, which promotes YAP/TAZ activity, and YAP/TAZ in turn upregulates NUAK1; fibroblast-specific NUAK1 loss attenuated kidney, lung, and liver fibrosis.

    Evidence Fibroblast-specific NUAK1 KO in multiple organ fibrosis mouse models with SMAD/YAP signaling analysis

    PMID:35320001

    Open questions at the time
    • Direct NUAK1 substrate in YAP/TAZ activation pathway not identified
    • Whether PP1β-MYPT1 mediates the fibrogenic loop
  15. 2022 High

    hnRNP A1 was identified as a direct NUAK1 substrate: NUAK1 phosphorylates serine residues within the F-peptide region of hnRNP A1, controlling its cytoplasmic relocalization during hypertonic stress, expanding NUAK1's role into RNA-binding protein regulation.

    Evidence In vitro kinase assay, M9-motif mutagenesis, RNAi kinome screen, co-IP

    PMID:35963429

    Open questions at the time
    • Specific phosphorylation sites on hnRNP A1 not individually mapped
    • Functional consequences for mRNA splicing or stability not determined
  16. 2023 Medium

    NUAK1 was found to govern centrosome duplication fidelity through the MYPT1/PP1β/GSK3β/PLK4 axis, with NUAK1 loss triggering centrosome amplification and genomic instability in both cancer cells and primary fibroblasts.

    Evidence NUAK1 depletion/inhibition with centrosome counting and genomic instability assays in PDAC cells and fibroblasts

    PMID:36975767

    Open questions at the time
    • Direct phosphorylation of PLK4 pathway components by NUAK1 not shown
    • Whether centrosome defects contribute to the senescence phenotype previously observed
  17. 2023 Medium

    NUAK1 was shown to interact with mTORC2 components and directly phosphorylate Akt at Ser473 while controlling lysosome positioning to regulate mTOR–lysosome association, selectively activating Akt/FOXO signaling over Akt/TSC2 signaling.

    Evidence Co-IP of mTORC2 components, in vitro kinase assay for Akt S473, lysosome positioning and subcellular fractionation

    PMID:38135881

    Open questions at the time
    • Mechanism of substrate-selective Akt signaling not explained
    • Single lab; independent validation needed
    • Whether NUAK1 phosphorylation of Akt is physiologically relevant given mTORC2 dominance
  18. 2024 High

    The metabolic function of NUAK1 in neurons was deepened: NUAK1 deficiency impairs mitochondrial metabolism and axonal ATP levels, and upregulation of mitochondrial function via the microprotein BRAWNIN rescues axon branching defects, demonstrating NUAK1 controls both mitochondrial distribution and metabolic output.

    Evidence Conditional NUAK1 KO, ATP biosensors, BRAWNIN knockdown/overexpression, in vivo axon branching

    PMID:38514619

    Open questions at the time
    • Whether NUAK1 directly regulates BRAWNIN expression or activity
    • How mitochondrial metabolic and anchoring functions are coordinated
  19. 2024 High

    NADK was identified as a direct NUAK1 substrate (Ser64), linking NUAK1 to NADPH metabolism and ROS control; this phosphorylation confers osimertinib resistance in NSCLC, extending NUAK1's roles to drug resistance via redox balance.

    Evidence In vitro kinase assay identifying NADK S64, NUAK1 knockdown/overexpression, ROS measurements, in vivo drug sensitivity

    PMID:39159134

    Open questions at the time
    • Whether NADK Ser64 phosphorylation alters enzymatic kinetics directly
    • Generalizability to other EGFR-TKI resistance contexts
  20. 2024 Medium

    The first crystal structures of NUAK1 were determined, revealing inhibitor binding modes and a unique Glu139 residue exploitable for selective inhibitor design, providing a structural foundation for drug development.

    Evidence X-ray crystallography of NUAK1 chimeric protein with bound inhibitors

    PMID:39588908

    Open questions at the time
    • Structure is of a chimeric construct, not full-length wild-type NUAK1
    • No structure of NUAK1 in complex with a substrate or regulatory subunit
  21. 2025 Medium

    USP9X was identified as a deubiquitinase that stabilizes and activates NUAK1, with the USP9X–NUAK1 axis promoting TGF-β1-induced myofibroblast transformation via Rho kinase signaling and driving cardiac fibrosis.

    Evidence Co-IP, myofibroblast-specific USP9X KO, in vivo myocardial infarction model

    PMID:40310323

    Open questions at the time
    • Direct ubiquitination sites on NUAK1 targeted by USP9X not mapped
    • Relationship between USP9X stabilization and SCFβTrCP-mediated degradation not clarified

Open questions

Synthesis pass · forward-looking unresolved questions
  • Key unresolved questions include: the full catalog of direct NUAK1 phosphorylation sites on MYPT1 and PNUTS; how nuclear versus cytoplasmic NUAK1 pools are coordinated to produce context-dependent metabolic and transcriptional outcomes; and whether NUAK1 haploinsufficiency is causative for human neurodevelopmental disorders.
  • No human genetic validation of NUAK1 as a Mendelian disease gene
  • No full-length wild-type NUAK1 structure
  • Mechanism by which NUAK1 selectively engages different substrates in different compartments unknown

Mechanism profile

Synthesis pass · controlled-vocabulary classification · explore literature graph →
Molecular activity
GO:0140096 catalytic activity, acting on a protein 10 GO:0098772 molecular function regulator activity 4
Localization
GO:0005634 nucleus 4 GO:0005739 mitochondrion 3 GO:0005829 cytosol 2 GO:0005768 endosome 1
Pathway
R-HSA-162582 Signal Transduction 7 R-HSA-1430728 Metabolism 5 R-HSA-1266738 Developmental Biology 3 R-HSA-1640170 Cell Cycle 3 R-HSA-1643685 Disease 3 R-HSA-5357801 Programmed Cell Death 3 R-HSA-8953854 Metabolism of RNA 2 R-HSA-8953897 Cellular responses to stimuli 2 R-HSA-74160 Gene expression (Transcription) 1
Partners
LATS1LKB1MYPT1PLK1PNUTSPP1BTP53USP9X

Evidence

Reading pass · 39 per-paper findings extracted from the source corpus
Year Finding Method Journal Conf PMIDs
2013 LKB1 directly activates NUAK1 kinase, and the LKB1-NUAK1 pathway controls axon branching in cortical neurons by promoting mitochondria immobilization at nascent presynaptic sites; conditional deletion of LKB1 or NUAK1 knockdown drastically reduces axon branching in vivo, while overexpression increases branching, and manipulation of Syntaphilin (a mitochondrial anchor) phenocopies NUAK1 effects. Conditional knockout, in utero knockdown/overexpression, live imaging, Syntaphilin genetic manipulation in mouse cortical neurons Cell High 23791179
2016 NUAK1 phosphorylates tau at Ser356, stabilizing tau protein levels; inhibition of NUAK1 in Drosophila suppresses neurodegeneration in tau-expressing flies, and NUAK1 haploinsufficiency rescues tauopathy phenotypes in a mouse model. Cell-based and Drosophila genetic screens, in vitro phosphorylation assay, tauopathy mouse model Neuron High 27720485
2003 ARK5/NUAK1 suppresses cell death (induced by nutrient starvation, TRAIL, and TNF-α) by inhibiting caspase 8 activation, delaying Bid cleavage and FLIP degradation. Overexpression in HepG2 cells, Western blot for caspase 8 activation, Bid cleavage, FLIP degradation Oncogene Medium 13679856
2004 ARK5/NUAK1 directly phosphorylates caspase-6 at Ser257 in vitro, preventing procaspase-6 activation and thereby suppressing Fas-mediated cell death in colorectal cancer cells; mutation of Ser257 to Ala abolishes this protection. In vitro kinase assay with wild-type and S257A mutant caspase-6, antisense RNA knockdown, Western blot Oncogene High 15273717
2004 ARK5/NUAK1 is activated downstream of Akt and promotes tumor invasion by inducing activation of MMP-2, MMP-9, and MT1-MMP via rapamycin-sensitive signaling; ARK5 overexpression in PANC-1 cells leads to invasion and metastasis in nude mice. Matrigel invasion assay, nude mouse xenograft, Western blot for MMP activation, pharmacological inhibition Molecular and cellular biology Medium 15060171
2006 NDR2 kinase phosphorylates ARK5/NUAK1 at Thr211 on the T-loop during IGF-1 signaling, providing full kinase activation; Akt phosphorylates ARK5 at Ser600 in the regulatory domain, and combined phosphorylation at T211 (by NDR2) and S600 (by Akt) is required for full ARK5 activity. In vitro kinase assay, mutant constructs, co-immunoprecipitation, IGF-1 stimulation in colorectal cancer cells The Journal of biological chemistry High 16488889
2005 ARK5/NUAK1 is transcriptionally regulated by the Large-MAF family transcription factors (c-MAF and MAFB) through MAF-recognition element (MARE) sequences in the ARK5 promoter; ARK5 mediates IGF-1-induced cell invasion in multiple myeloma. Chromatin immunoprecipitation, promoter reporter assay with MARE deletion/mutation, gene expression profiling Oncogene High 16044163
2009 NUAK1 phosphorylates LATS1 at Ser464, promoting its degradation and thereby controlling cellular ploidy and senescence; NUAK1 overexpression triggers premature senescence and aneuploidies, while a dominant-negative LATS1 phenocopies NUAK1 effects. Loss-of-function screen, shRNA depletion, overexpression, in vitro kinase assay for LATS1 phosphorylation The EMBO journal High 19927127
2011 NUAK1 directly interacts with and phosphorylates p53 in vitro and in vivo in a LKB1-dependent manner; phosphorylation of NUAK1 at Thr211 by LKB1 is required for NUAK1 kinase activity; the LKB1/NUAK1/p53 axis induces G1/S cell cycle arrest via p21/WAF1 and NUAK1 associates with p53 in the nucleus at the p21 promoter. Co-immunoprecipitation, in vitro kinase assay, chromatin immunoprecipitation, cell cycle analysis Oncogene High 21317932
2012 Muscle-specific knockout of NUAK1 prevents high-fat diet-induced glucose intolerance; NUAK1 suppresses insulin signaling by promoting phosphorylation of IRS1 at Ser1097; loss of NUAK1 enhances phosphorylation of IRS1 Tyr608, AKT Thr308, and TBC1D4 Thr649, improving glucose uptake. Muscle-specific knockout mice, glucose tolerance test, quantitative phosphoproteomics of soleus muscle The Journal of biological chemistry High 22418434
2012 NUAK1 and NUAK2 together (but not individually) are required for apical constriction and apico-basal elongation during dorsolateral hinge point formation in neural plate; double mutants show defective apical concentration of phosphorylated myosin light chain 2, F-actin, and cortactin, causing neural tube defects. Double knockout mouse model, immunofluorescence for cytoskeletal markers Developmental dynamics Medium 22689267
2014 NUAK1 expression is controlled through the cell cycle by CDK phosphorylation at Ser445, which triggers PLK1 binding; PLK1 then phosphorylates NUAK1 at Ser476 and Ser480, promoting binding to βTrCP and SCFβTrCP-mediated ubiquitylation and degradation; NUAK1 inhibits the PP1β-MYPT1 phosphatase complex and thereby promotes PLK1 T-loop phosphorylation at Thr210, establishing a reciprocal regulatory loop. Biochemical fractionation, co-immunoprecipitation, in vitro phosphorylation, ubiquitylation assay, NUAK1 inhibitors (WZ4003, HTH-01-015), site-directed mutagenesis The Biochemical journal High 24785407
2013 NUAK1 is a direct target of miR-211, which is regulated by the MITF transcription factor; miR-211 suppresses NUAK1 expression and promotes melanoma cell adhesion, thereby inhibiting the invasive program. miRNA overexpression/inhibition, luciferase reporter assay for 3'UTR targeting, adhesion assays The Journal of investigative dermatology Medium 23934065
2018 NUAK1 is activated by oxidative stress and facilitates nuclear import of the antioxidant master regulator NRF2 by coordinating PP1β inhibition with AKT activation to suppress GSK3β-dependent inhibition of NRF2 nuclear import; deletion of NUAK1 suppresses colorectal tumor formation and causes regression of established tumors. NUAK1 conditional knockout, autochthonous colorectal tumor models, Western blot for PP1β, AKT, GSK3β, NRF2 nuclear fractionation Cancer discovery High 29500295
2020 NUAK1 is a predominantly nuclear kinase that phosphorylates PNUTS (a nuclear regulatory subunit of PP1) to locally inhibit PP1 activity; NUAK1-PNUTS interaction is required for chromatin association of PNUTS, spliceosome activity, and nascent RNA synthesis; in MYC-overexpressing cells, NUAK1 inhibition causes global RNAPII accumulation at the pause site and first exon-intron boundary without increasing mRNA synthesis. Nuclear/cytoplasmic fractionation, co-immunoprecipitation of PP1 interactor network, in vitro kinase assay of PNUTS, NUAK1 inhibition, RNAPII ChIP, nascent RNA synthesis assay Molecular cell High 32006464
2022 TGF-β induces rapid NUAK1 upregulation in fibroblasts; NUAK1 in turn promotes YAP/TAZ and TGF-β/SMAD profibrotic signaling; activated YAP/TAZ further induces NUAK1 expression, creating a positive feedback loop; fibroblast-specific loss or pharmacological inhibition of NUAK1 markedly attenuates kidney, lung, and liver fibrosis in mouse models. Fibroblast-specific NUAK1 knockout, mouse models of organ fibrosis, Western blot for SMAD/YAP signaling, pharmacological inhibition Science translational medicine High 35320001
2019 NUAK1 nuclear import is mediated by a bipartite nuclear localization signal at its N-terminal domain and requires importin-β members KPNB1, IPO7, and IPO9; oxidative stress induces NUAK1 cytoplasmic accumulation by affecting its nuclear transport. Cell fractionation, mass spectrometry identification of importin interactors, importin-β knockdown, Importazole treatment, NLS mutant constructs Journal of cellular biochemistry Medium 31090959
2017 In tumor cells lacking LKB1, NUAK1 kinase activity is maintained by an alternative calcium-dependent pathway involving PKCα activation; calcium/PKCα-dependent NUAK1 activation supports AMPK-TORC1 metabolic checkpoint engagement, protecting tumor cells from MYC-driven cell death; MYC transcriptionally regulates PKCα and ITPR to promote this pathway. LKB1-null cell models, PKCα knockdown/inhibition, calcium manipulation, MYC transcriptomics, TORC1 signaling assays Oncogene Medium 29106388
2020 Cytosolic NUAK1 increases ATP production by enhancing mitochondrial respiration; NUAK1 inhibition leads to mitochondrial morphology changes ('donut-like' structures); nuclear NUAK1 is involved in the metabolic switch to glycolysis; NUAK1 subcellular localization differentially affects metabolic outcomes in cancer cells. Subcellular fractionation, mitochondrial respiration assays, ATP measurements, live-cell imaging of mitochondrial morphology, NUAK1 inhibition Frontiers in oncology Medium 32754444
2024 NUAK1 deficiency significantly impairs mitochondrial metabolism and axonal ATP concentration in cortical neurons; upregulation of mitochondrial function rescues axon branching defects in NUAK1-null neurons in vitro and in vivo; NUAK1 regulates axon branching through the mitochondria-targeted microprotein BRAWNIN, demonstrating a dual function controlling both mitochondrial distribution and metabolic activity. NUAK1 conditional knockout, mitochondrial function assays, ATP biosensors, BRAWNIN knockdown/overexpression, in vivo axon branching quantification Nature communications High 38514619
2020 LKB1 phosphorylates and stabilizes NUAK1 in ovarian cancer spheroids; NUAK1 loss reduces spheroid integrity and fibronectin (FN1) expression (745-fold decrease); fibronectin is required for compact spheroid formation and metastasis; NUAK1 loss extends survival in a xenograft model of intraperitoneal metastasis. NUAK1 knockout, transcriptome analysis, fibronectin rescue experiments, xenograft metastasis model Cancers Medium 32429240
2022 ARK5/NUAK1 directly interacts with and phosphorylates hnRNP A1 on serine residues within the F-peptide region; the M9 motif of hnRNP A1 is required for ARK5 interaction and phosphorylation; ARK5-mediated phosphorylation controls hnRNP A1 cytoplasmic relocalization during hypertonic stress; ARK5 silencing increases Bcl-xL expression and delays caspase activation. Co-immunoprecipitation, in vitro kinase assay, RNAi-based kinome screen, flow cytometry for caspase activation The Journal of biological chemistry High 35963429
2023 NUAK1 governs accurate centrosome duplication via MYPT1/PP1β and GSK3β-dependent regulation of PLK4; loss of NUAK1 triggers genomic instability in both pancreatic cancer cells and primary fibroblasts. NUAK1 inhibition/depletion, centrosome counting, genomic instability assays, pathway analysis in PDAC cells Molecular oncology Medium 36975767
2023 NUAK1 promotes metastasis in esophageal squamous cell carcinoma by activating the JNK/c-Jun pathway, which upregulates Slug transcription; silencing Slug completely abolishes NUAK1-overexpression-driven migration and invasion. Co-immunoprecipitation, immunofluorescence, dual-luciferase reporter gene assay for Slug promoter, in vivo pulmonary metastasis model Cancer cell international Medium 37919754
2024 NUAK1 directly phosphorylates NADK (nicotinamide adenine dinucleotide kinase) at Ser64, reducing ROS accumulation and thereby conferring osimertinib resistance in NSCLC; genetic or pharmacological blockade of NUAK1 restores osimertinib sensitivity. In vitro kinase assay identifying NADK S64 phosphorylation, NUAK1 knockdown/overexpression, ROS measurements, in vitro and in vivo drug sensitivity assays Cancer research High 39159134
2023 NUAK1 interacts with mTORC2 components and regulates mTORC2-dependent Akt activation by controlling lysosome positioning and mTOR association with lysosomes; NUAK1 also directly phosphorylates Akt at Ser473; NUAK1 is associated with early endosomes and selectively promotes Akt/FOXO1/3a signaling but not Akt/TSC2 signaling. Co-immunoprecipitation of mTORC2 components, in vitro kinase assay for Akt S473, lysosome positioning assay, subcellular fractionation, Akt substrate phosphorylation analysis Cell & bioscience Medium 38135881
2024 NUAK1 upregulates GLI1 expression by activating STAT5-mediated transcription and stabilizing GLI1 protein; depletion or inhibition of NUAK1 impairs cancer cell expansion and tumor formation via the NUAK1/STAT5/GLI1 axis in gastric cancer. Patient-derived xenograft, transgenic mouse model, siRNA knockdown, pharmacological inhibition, Western blot and reporter assays for STAT5/GLI1 Cell reports Medium 38996065
2020 In yeast, Tda1 (the ortholog of human NUAK1) directly phosphorylates histone H3 at Thr11 upon low glucose stress; yeast AMPK (Snf1) phosphorylates Tda1 to govern its activity, while CK2 regulates Tda1 nuclear localization; AMPK and CK2 signaling converge on histone kinase Tda1 to link glucose stress to chromatin regulation. In vitro kinase assay, H3pT11 ChIP, mutant analysis, epistasis in budding yeast eLife High 33372657
2025 USP9X deubiquitinates and thereby activates ARK5/NUAK1; USP9X-activated NUAK1 promotes TGF-β1-induced myofibroblast transformation via the Rho kinase pathway; myofibroblast-specific USP9X knockout or pharmacological inhibition reduces NUAK1 activity and attenuates cardiac fibrosis. Co-immunoprecipitation, USP9X knockout (myofibroblast-specific), in vivo myocardial infarction model, Western blot for NUAK1 ubiquitination/activation and Rho kinase pathway JACC. Basic to translational science Medium 40310323
2024 ARK5/NUAK1 regulates mitochondrial morphological dynamics, promoting fission over fusion in multiple myeloma cells; ARK5 knockout cells show enhanced mitochondrial fusion, reduced phosphorylation of DRP1 at Ser616, higher MFN1/MFN2 expression, lower ATP, higher lactate, and higher ROS levels. Biallelic ARK5 knockout in myeloma cell lines, mitochondrial morphology imaging, Western blot for DRP1/MFN1/MFN2, ATP and lactate measurements Cell death discovery Medium 38282096
2021 NUAK1 facilitates nuclear import of NRF2 by inhibiting PP1β, which leads to AKT activation and suppression of GSK3β-dependent phosphorylation of NRF2, thus reducing GSK3β-mediated inhibition of NRF2 nuclear import; silencing NUAK1 upregulates PP1β and downregulates phospho-GSK3βSer9, suppressing NRF2 nuclear accumulation and GPX4 expression. siRNA knockdown, Western blot for PP1β, p-GSK3βSer9, NRF2 nuclear fractionation, NUAK1 agonist rescue experiment Aging Medium 33819186
2018 Haploinsufficiency of NUAK1 in mice impairs cortical axon branching and leads to behavioral deficits including defective spatial memory consolidation, impaired social novelty, and abnormal sensorimotor gating, confirming NUAK1 as a haploinsufficient autism spectrum disorder candidate gene. NUAK1 heterozygous knockout mice, cortical connectivity analysis, behavioral test battery Nature communications High 30327473
2024 NUAK1 promotes PD-L1 transcription in hepatocellular carcinoma by phosphorylating GSK3β at Ser9, which activates β-catenin nuclear accumulation and PD-L1 gene expression; knockdown of β-catenin reverses NUAK1-mediated PD-L1 upregulation. Gain and loss of function experiments, Western blot and immunofluorescence for GSK3β/β-catenin/PD-L1, β-catenin knockdown rescue, IHC of patient samples Molecular medicine (Cambridge, Mass.) Medium 39901136
2025 NUAK1 is present in human erythrocytes and undergoes increased phosphorylation in P. falciparum-infected cells; NUAK1 inhibition reduces MYPT1 phosphorylation in erythroid cells; genetic overexpression of NUAK1 in erythroid cells partially rescues both signaling and parasite invasion phenotypes caused by NUAK1 inhibitors. Chemoproteomic profiling confirming inhibitor selectivity, phosphoproteomic analysis, NUAK1 overexpression in erythroid cells, P. falciparum invasion assays bioRxiv (PMID available: 41278793)preprint Medium 41278793
2025 NUAK1 phosphorylates the splicing co-factor SON, regulating a conserved set of alternative splicing events in genes crucial for neurodevelopment in cortical neurons; SON is required for proper cortical neuron development consistent with ZTTK syndrome phenotypes. NUAK1 conditional knockout in cortical neurons, RNA splicing analysis, identification of SON as phosphorylation substrate, SON knockdown bioRxivpreprint Medium
2024 NUAK1 kinase activity correlates with MYPT1 phosphorylation at Ser445 and Ser910 in vascular smooth muscle cells; NUAK1 knockdown decreases myosin light chain phosphorylation, potentially by increasing MYPT1 phosphatase activity, reducing contractility and altering F-actin cytoskeletal organization. Phosphoproteomic analysis, NUAK1 knockdown, pMLC and MYPT1 phosphorylation Western blot, impedance-based contraction assay bioRxivpreprint Low
2024 First crystal structures of a NUAK1 chimeric protein were determined, providing structural insights into inhibitor binding modes and identifying a unique glutamate residue (Glu139) that can be exploited for selective NUAK1 targeting. X-ray crystallography of NUAK1 chimeric protein with bound inhibitors Journal of medicinal chemistry Medium 39588908
2022 ARK5/NUAK1 prevents degradation of TGF-β type I receptor (TβRI) and Smad4 proteins by inhibiting Smurf2 expression in hepatic stellate cells, thereby maintaining TGF-β signaling; in hepatocytes, ARK5 induces EMT and promotes inflammatory cytokine secretion, synergistically driving liver fibrosis. ARK5 knockdown in HSCs and hepatocytes, Western blot for TβRI/Smad4/Smurf2, mouse CCl4-fibrosis model with HTH-01-015 inhibitor International journal of molecular sciences Medium 36361872
2024 NUAK1 promotes pyroptosis and inflammation in MASH by activating Caspase 6; NUAK1/Caspase 6 axis inhibition accelerates the interaction between TAK1 and RIPK1, leading to RIPK1 degradation and suppression of hepatic inflammation. NUAK1 inhibition in vivo and in vitro MASH models, Western blot for Caspase 6, TAK1, RIPK1, caspase 6 disruption experiments Hepatology communications Medium 38967580

Source papers

Stage 0 corpus · 93 papers · ranked by NIH iCite citations
Year Title Journal Citations PMID
2013 Terminal axon branching is regulated by the LKB1-NUAK1 kinase pathway via presynaptic mitochondrial capture. Cell 280 23791179
2021 Suppressing the KIF20A/NUAK1/Nrf2/GPX4 signaling pathway induces ferroptosis and enhances the sensitivity of colorectal cancer to oxaliplatin. Aging 132 33819186
2016 Reduction of Nuak1 Decreases Tau and Reverses Phenotypes in a Tauopathy Mouse Model. Neuron 123 27720485
2004 ARK5 is a tumor invasion-associated factor downstream of Akt signaling. Molecular and cellular biology 112 15060171
2013 Transcription factor/microRNA axis blocks melanoma invasion program by miR-211 targeting NUAK1. The Journal of investigative dermatology 97 23934065
2014 MiR-204 inhibits human NSCLC metastasis through suppression of NUAK1. British journal of cancer 96 25412236
2009 Regulation of ploidy and senescence by the AMPK-related kinase NUAK1. The EMBO journal 93 19927127
2022 NUAK1 promotes organ fibrosis via YAP and TGF-β/SMAD signaling. Science translational medicine 85 35320001
2018 Colorectal Tumors Require NUAK1 for Protection from Oxidative Stress. Cancer discovery 79 29500295
2003 ARK5 suppresses the cell death induced by nutrient starvation and death receptors via inhibition of caspase 8 activation, but not by chemotherapeutic agents or UV irradiation. Oncogene 77 13679856
2004 Regulation of caspase-6 and FLIP by the AMPK family member ARK5. Oncogene 76 15273717
2018 LncRNA SNHG1 functions as a ceRNA to antagonize the effect of miR-145a-5p on the down-regulation of NUAK1 in nasopharyngeal carcinoma cell. Journal of cellular and molecular medicine 67 29575772
2011 A new role of NUAK1: directly phosphorylating p53 and regulating cell proliferation. Oncogene 65 21317932
2005 ARK5 is transcriptionally regulated by the Large-MAF family and mediates IGF-1-induced cell invasion in multiple myeloma: ARK5 as a new molecular determinant of malignant multiple myeloma. Oncogene 60 16044163
2004 ARK5 expression in colorectal cancer and its implications for tumor progression. The American journal of pathology 59 14982852
2012 ARK5 promotes glioma cell invasion, and its elevated expression is correlated with poor clinical outcome. European journal of cancer (Oxford, England : 1990) 58 23063350
2016 microRNA-203 suppresses invasion and epithelial-mesenchymal transition induction via targeting NUAK1 in head and neck cancer. Oncotarget 57 26882562
2019 miR-424-5p represses the metastasis and invasion of intrahepatic cholangiocarcinoma by targeting ARK5. International journal of biological sciences 52 31360102
2014 miR‑96 functions as a tumor suppressor gene by targeting NUAK1 in pancreatic cancer. International journal of molecular medicine 49 25242509
2014 Discovery of 8-cyclopentyl-2-[4-(4-methyl-piperazin-1-yl)-phenylamino]-7-oxo-7,8-dihydro-pyrido[2,3-d]pyrimidine-6-carbonitrile (7x) as a potent inhibitor of cyclin-dependent kinase 4 (CDK4) and AMPK-related kinase 5 (ARK5). Journal of medicinal chemistry 48 24417566
2020 Localized Inhibition of Protein Phosphatase 1 by NUAK1 Promotes Spliceosome Activity and Reveals a MYC-Sensitive Feedback Control of Transcription. Molecular cell 45 32006464
2016 ARK5 promotes doxorubicin resistance in hepatocellular carcinoma via epithelial-mesenchymal transition. Cancer letters 45 27126361
2015 Activation of ARK5/miR-1181/HOXA10 axis promotes epithelial-mesenchymal transition in ovarian cancer. Oncology reports 45 26151663
2004 Strong association of ARK5 with tumor invasion and metastasis. Journal of experimental & clinical cancer research : CR 43 15354411
2011 ARK5 is associated with the invasive and metastatic potential of human breast cancer cells. Journal of cancer research and clinical oncology 41 22105900
2019 MiR-204 inhibits hepatocellular cancer drug resistance and metastasis through targeting NUAK1. Biochemistry and cell biology = Biochimie et biologie cellulaire 40 30807203
2017 Knockdown of ARK5 Expression Suppresses Invasion and Metastasis of Gastric Cancer. Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology 35 28662499
2020 Dual targeting of NUAK1 and ULK1 using the multitargeted inhibitor MRT68921 exerts potent antitumor activities. Cell death & disease 33 32873786
2012 Muscle-specific knock-out of NUAK family SNF1-like kinase 1 (NUAK1) prevents high fat diet-induced glucose intolerance. The Journal of biological chemistry 32 22418434
2012 Neural tube defects by NUAK1 and NUAK2 double mutation. Developmental dynamics : an official publication of the American Association of Anatomists 31 22689267
2017 Calcium signalling links MYC to NUAK1. Oncogene 29 29106388
2015 MiR-145 functions as a tumor suppressor targeting NUAK1 in human intrahepatic cholangiocarcinoma. Biochemical and biophysical research communications 29 26255969
2020 A novel role for NUAK1 in promoting ovarian cancer metastasis through regulation of fibronectin production in spheroids. Cancers 28 32429240
2006 NDR2 acts as the upstream kinase of ARK5 during insulin-like growth factor-1 signaling. The Journal of biological chemistry 28 16488889
2016 Dual Targeting of CDK4 and ARK5 Using a Novel Kinase Inhibitor ON123300 Exerts Potent Anticancer Activity against Multiple Myeloma. Cancer research 27 26873845
2018 Haploinsufficiency of autism spectrum disorder candidate gene NUAK1 impairs cortical development and behavior in mice. Nature communications 25 30327473
2014 Interplay between Polo kinase, LKB1-activated NUAK1 kinase, PP1βMYPT1 phosphatase complex and the SCFβTrCP E3 ubiquitin ligase. The Biochemical journal 25 24785407
2021 NUAK1 and NUAK2 Fine-Tune TGF-β Signaling. Cancers 22 34282782
2020 miR-622 is a novel potential biomarker of breast carcinoma and impairs motility of breast cancer cells through targeting NUAK1 kinase. British journal of cancer 22 32418991
2025 Targeting the mevalonate pathway potentiates NUAK1 inhibition-induced immunogenic cell death and antitumor immunity. Cell reports. Medicine 20 39824180
2024 The AMPK-related kinase NUAK1 controls cortical axons branching by locally modulating mitochondrial metabolic functions. Nature communications 20 38514619
2020 Cytosolic NUAK1 Enhances ATP Production by Maintaining Proper Glycolysis and Mitochondrial Function in Cancer Cells. Frontiers in oncology 20 32754444
2017 Inhibition of AMPK-related kinase 5 (ARK5) enhances cisplatin cytotoxicity in non-small cell lung cancer cells through regulation of epithelial-mesenchymal transition. American journal of translational research 20 28469776
2021 MicroRNA-1182 and let-7a exert synergistic inhibition on invasion, migration and autophagy of cholangiocarcinoma cells through down-regulation of NUAK1. Cancer cell international 19 33750398
2019 Identification of a nuclear localization signal and importin beta members mediating NUAK1 nuclear import inhibited by oxidative stress. Journal of cellular biochemistry 18 31090959
2019 LINC00958 Promotes The Malignancy Of Nasopharyngeal Carcinoma By Sponging microRNA-625 And Thus Upregulating NUAK1. OncoTargets and therapy 18 31819474
2022 Loss of LKB1-NUAK1 signalling enhances NF-κB activity in a spheroid model of high-grade serous ovarian cancer. Scientific reports 17 35194062
2021 Role of ARK5 in cancer and other diseases (Review). Experimental and therapeutic medicine 16 33986861
2017 Salinomycin enhances doxorubicin sensitivity through reversing the epithelial-mesenchymal transition of cholangiocarcinoma cells by regulating ARK5. Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas 15 28832761
2021 LINC00922 promotes the proliferation, migration, invasion and EMT process of liver cancer cells by regulating miR-424-5p/ARK5. Molecular and cellular biochemistry 14 34097192
2020 LncRNA NEAT1/miR-204/NUAK1 Axis is a Potential Therapeutic Target for Non-Small Cell Lung Cancer. Cancer management and research 14 33402847
2018 AMPK-related kinase 5 (ARK5) enhances gemcitabine resistance in pancreatic carcinoma by inducing epithelial-mesenchymal transition. American journal of translational research 14 30662653
2023 NUAK1 governs centrosome replication in pancreatic cancer via MYPT1/PP1β and GSK3β-dependent regulation of PLK4. Molecular oncology 13 36975767
2018 NUAK1 knockdown suppresses prostate cancer cell epithelial-mesenchymal transition, migration, and invasion through microRNA-30b-5p. International journal of clinical and experimental pathology 13 31949655
2024 NUAK1-Mediated Phosphorylation of NADK Mitigates ROS Accumulation to Promote Osimertinib Resistance in Non-Small Cell Lung Carcinoma. Cancer research 12 39159134
2023 LncRNA HOTAIR Enhances Epithelial-to-mesenchymal Transition to Promote the Migration and Invasion of Liver Cancer by Regulating NUAK1 via Epigenetic Inhibition miR-145-5p Expression. Journal of Cancer 12 37576402
2024 NUAK1 activates STAT5/GLI1/SOX2 signaling to enhance cancer cell expansion and drives chemoresistance in gastric cancer. Cell reports 11 38996065
2011 Identification and prioritization of NUAK1 and PPP1CC as positional candidate loci for skeletal muscle strength phenotypes. Physiological genomics 11 21750233
2023 Inhibition of growth and contraction in human prostate stromal cells by silencing of NUAK1 and -2, and by the presumed NUAK inhibitors HTH01-015 and WZ4003. Frontiers in pharmacology 10 37188272
2024 ARK5 enhances cell survival associated with mitochondrial morphological dynamics from fusion to fission in human multiple myeloma cells. Cell death discovery 9 38282096
2020 Yeast Nuak1 phosphorylates histone H3 threonine 11 in low glucose stress by the cooperation of AMPK and CK2 signaling. eLife 9 33372657
2023 NUAK1 promotes tumor metastasis through upregulating slug transcription in esophageal squamous cell carcinoma. Cancer cell international 8 37919754
2023 NUAK1 coordinates growth factor-dependent activation of mTORC2 and Akt signaling. Cell & bioscience 8 38135881
2014 Analysis of NUAK1 and NUAK2 expression during early chick development reveals specific patterns in the developing head. The International journal of developmental biology 8 25354459
2022 Discovery of a novel NUAK1 inhibitor against pancreatic cancer. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 7 35691157
2017 ARK5 promotes invasion and migration in hepatocellular carcinoma cells by regulating epithelial-mesenchymal transition. Oncology letters 7 29434843
2022 DKK1 promotes NUAK1 transcriptional expression through the activation Akt in hepatocellular carcinoma. Cell biology international 6 36480792
2019 Knockdown of ARK5 expression suppresses invasion of ovarian cancer cells. Molecular medicine reports 6 30720082
2024 NUAK1 promotes metabolic dysfunction-associated steatohepatitis progression by activating Caspase 6-driven pyroptosis and inflammation. Hepatology communications 5 38967580
2022 miR-622 Counteracts the NUAK1-Induced Gastric Cancer Cell Proliferation and the Antioxidative Stress. Disease markers 5 35872695
2022 Enhanced Expression of ARK5 in Hepatic Stellate Cell and Hepatocyte Synergistically Promote Liver Fibrosis. International journal of molecular sciences 5 36361872
2020 WZ4003 sensitizes non-small cell lung cancer cells to gefitinib via inhibition of ARK5 and epithelial-to-mesenchymal transition. American journal of translational research 5 33312374
2017 Retraction: Wang, L., Ma, X., Yan, L., Wang, T., Wen, J. and Mi, G., LncRNA SNHG1 negatively regulates miR-145a-5p to enhance NUAK1 expression and promote cancer cell metastasis and invasion in nasopharyngeal carcinoma. J Cell Physiol. Accepted Author Manuscript. doi:10.1002/jcp.26340. Journal of cellular physiology 5 29215719
2024 1,2-bis(2,4,6-tribromophenoxy) ethane induces necroptosis via the co-competition of GAS5 and NUAK1 for miR-743a-5p in rat hepatocytes. Journal of hazardous materials 4 39141942
2022 AMPK-related protein kinase ARK5 regulates subcellular localization of RNA-binding protein hnRNP A1 during hypertonic stress. The Journal of biological chemistry 4 35963429
2022 Circ_0003998 upregulates ARK5 expression to elevate 5-Fluorouracil resistance in hepatocellular carcinoma through binding to miR-513a-5p. Anti-cancer drugs 4 36255069
2025 NUAK1 acts as a novel regulator of PD-L1 via activating GSK-3β/β-catenin pathway in hepatocellular carcinoma. Molecular medicine (Cambridge, Mass.) 3 39901136
2024 Discovery of UCB9386: A Potent, Selective, and Brain-Penetrant Nuak1 Inhibitor Suitable for In Vivo Pharmacological Studies. Journal of medicinal chemistry 3 39588908
2023 Evaluation of ARK5 and SIRT3 expression in renal cell carcinoma and their clinical significance. Diagnostic pathology 3 37996927
2021 [Role of miR-145-5p Targeting ARK5 in Regulating the Proliferation and Apoptosis of Human Epithelial Ovarian Cancer Cells]. Zhongguo yi xue ke xue yuan xue bao. Acta Academiae Medicinae Sinicae 3 34728027
2025 Ubiquitin Specific Protease 9X Regulates the Activation of ARK5 and Promotes Progression of Fibrotic Remodeling. JACC. Basic to translational science 2 40310323
2020 Silencing of the ARK5 gene reverses the drug resistance of multidrug-resistant SGC7901/DDP gastric cancer cells. PeerJ 2 32844054
2025 Development of the Pyrido[2,3-d]pyrimidin-7(8H)-one Scaffold toward Potent and Selective NUAK1 Inhibitors. ACS medicinal chemistry letters 1 39967649
2025 Functional characterization of key protein biomarkers in spontaneous intracerebral hemorrhage pathogenesis: Structure and function of NUAK1 protein and ERO1L protein macromolecules. International journal of biological macromolecules 1 40203915
2025 NUAK1 Promotes Diabetic Kidney Disease by Accelerating Renal Tubular Senescence via the ROS/P53 Axis. Diabetes 1 41264843
2020 Splice or Die: When MYC Is Driving, Transcription Needs NUAK1 to Avoid Fatal Pileups. Molecular cell 1 32200795
2026 NUAK1 silencing enhances radiotherapy-induced ferroptosis in locally advanced rectal cancer by impairing Nrf2-driven transcription of GPX4. Cellular oncology (Dordrecht, Netherlands) 0 41848996
2026 Structure-Based Design of Potent and Highly Selective NUAK1 Inhibitors by Exploiting a Unique Glutamate Switch for the Prevention of Tumor Growth, Migration, and Invasion. Journal of medicinal chemistry 0 41855469
2026 Epigenetic inhibition of class I histone deacetylases by MS-275 attenuates diabetic skeletal muscle atrophy via Akt/ARK5-FoxO and myostatin-Smad signaling. Frontiers in endocrinology 0 41877927
2025 WZ4003 sensitizes hepatocellular carcinoma to OSI-027 by inhibiting ARK5-mediated autophagy. Cancer letters 0 40834984
2025 Development of Purine and Pyrrolopyrimidine Scaffolds as Potent, Selective, and Brain Penetrant NUAK1 Inhibitors. ACS medicinal chemistry letters 0 41257021
2025 Plasmodium falciparum exploits NUAK1 to establish infection in human erythrocytes. bioRxiv : the preprint server for biology 0 41278793
2016 [Construction of a RNAi lentiviral vector targeting ARK5 gene and its effect on the biological behavior of gastric cancer SGC7901 cells]. Zhonghua zhong liu za zhi [Chinese journal of oncology] 0 26899327